Jove
Visualize
Contact Us

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

397
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
397
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

533
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
533
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

367
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
367
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

532
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
532

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients.

Frontiers in pediatrics·2024
Same author

Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.

British journal of haematology·2023
Same author

[Endothelial dysfunction in thrombotic thrombocytopenic purpura: therapeutic perspectives].

La Revue de medecine interne·2021
Same author

[Acquired angioedema due to C1-inhibitor deficiency: CREAK recommendations for diagnosis and treatment].

La Revue de medecine interne·2020
Same author

[Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange].

La Revue de medecine interne·2020
Same author

Prognosis of Lymphoma in Patients With Known Inflammatory Bowel Disease: A French Multicentre Cohort Study.

Journal of Crohn's & colitis·2020
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 23, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.5K

[Secondary thrombotic microangiopathies].

P Coppo1, 1

  • 1Service d'hématologie, centre de référence des microangiopathies thrombotiques, hôpital Saint-Antoine, UPMC université Paris 6, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.

La Revue De Medecine Interne
|September 12, 2017
PubMed
Summary

Secondary thrombotic microangiopathies (TMA) require prompt recognition due to diverse causes and impacts on patient outcomes. Understanding pathophysiology and exploring new therapies, like complement blockers, are crucial for improving prognosis in these complex conditions.

Keywords:
Allogeneic hematopoietic stem cell transplantationAllogreffeCancerChemotherapyChimiothérapieEculizumabHIV infectionMicroangiopathie thrombotiqueThrombotic microangiopathyVIHÉculizumab

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.6K
Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres
08:29

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Published on: November 21, 2025

428

Related Experiment Videos

Last Updated: Feb 23, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.5K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.6K
Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres
08:29

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Published on: November 21, 2025

428

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Thrombotic microangiopathies (TMA) are classified as secondary when linked to specific conditions.
  • These include TMA associated with pregnancy, stem cell transplantation, cancer, drugs, or HIV infection.
  • Secondary TMA are a heterogeneous group with presentations dependent on the underlying context.

Purpose of the Study:

  • To highlight the importance of recognizing secondary TMA for effective management and prognosis.
  • To discuss the varying prognoses of different secondary TMA forms.
  • To emphasize the need for better understanding of pathophysiology and novel therapeutic strategies.

Main Methods:

  • Review of existing literature on secondary TMA.
  • Analysis of clinical presentations and outcomes based on associated contexts.
  • Discussion of current and emerging therapeutic approaches.

Main Results:

  • Pregnancy-associated TMA prognosis has improved with better understanding.
  • TMA associated with stem cell transplantation and chemotherapy still have poor prognoses.
  • Complement blockers show promising preliminary results.

Conclusions:

  • Recognizing secondary TMA is critical for patient management and prognosis.
  • Further research into pathophysiology and novel therapies is essential.
  • Emerging treatments like complement inhibitors offer hope for improved outcomes.